Clinical Edge Journal Scan

Early achievement of minimal disease activity important for long-term benefits in PsA


 

Key clinical point: The failure to achieve minimal disease activity (MDA) in the first year after the diagnosis of psoriatic arthritis (PsA) was associated with worse health-related quality of life and health status, functional impairment, fatigue, pain, and higher anxiety and depression.

Major finding: Compared with patients who achieved sustained MDA in the first year after diagnosis, those who did not achieve MDA had higher scores for pain (estimated mean difference [β] 35.38), fatigue (β 17.88), and functional ability (β 0.81; all P < .001) and higher anxiety and depression (both P < .001) during follow-up, which persisted despite treatment intensification.

Study details: This prospective cohort study included 240 patients with newly diagnosed PsA with oligoarthritis or polyarthritis who were disease-modifying antirheumatic drug naive.

Disclosures: This study was sponsored by UCB Pharma. S Welby and AR Prickett declared being stockholders of UCB.

Source: Snoeck Henkemans SVJ et al. Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis. RMD Open. 2022;8(2):e002706 (Dec 7). Doi: 10.1136/rmdopen-2022-002706

Recommended Reading

Meta-analysis fails to identify specific diagnostic biomarker for PsA
Psoriatic Arthritis ICYMI
Ustekinumab matches TNF inhibitors for psoriatic arthritis in 3-year, real-world study
Psoriatic Arthritis ICYMI
FDA approves Idacio as eighth adalimumab biosimilar in U.S.
Psoriatic Arthritis ICYMI
FDA will review pediatric indication for roflumilast cream
Psoriatic Arthritis ICYMI
Cardiovascular risk score multipliers suggested for rheumatic diseases
Psoriatic Arthritis ICYMI
Commentary: Bimekizumab, and PsA's Relationships With AS and Crohn's Disease, January 2023
Psoriatic Arthritis ICYMI
Topical psoriasis treatments
Psoriatic Arthritis ICYMI
Teamwork guides cardio-rheumatology clinics that care for unique patient population
Psoriatic Arthritis ICYMI
Psoriasis, psoriatic arthritis show distinctive skin microbiomes
Psoriatic Arthritis ICYMI
No benefits of concomitant methotrexate in PsA patients treated with ustekinumab
Psoriatic Arthritis ICYMI